At a glance
- Originator Japan Energy Corporation
- Developer Daiichi Fine Chemical; Japan Energy Corporation
- Class Antithrombotics; Oligopeptides
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Venous thrombosis
Most Recent Events
- 17 Jan 2001 Discontinued-Preclinical for Venous thrombosis in Japan (Unknown route)
- 22 Aug 1997 New profile
- 22 Aug 1997 Preclinical development for Venous thrombosis in Japan (Unknown route)